Hi Jonathan,
I'm following up on an email I sent introducing you to Inner Cosmos, a neurotechnology developing a minimally invasive brain-computer interface (BCI) implant that has demonstrated promising effectiveness for treatment-resistant depression.
Depression is the leading cause of disability worldwide, with over 21 million people in the U.S. alone undergoing treatment. However, 30% of patients find no relief from current medications. While Transcranial Magnetic Stimulation (TMS) is an FDA-approved and effective treatment, its logistical challenges—requiring 30 days of in-hospital treatment every 6–12 months—limit accessibility.
Inner Cosmos’s discreet, under-the-skin device delivers precise brain stimulation without penetrating the brain, enabling real-time mood management at home and greater accessibility for patients. Preliminary clinical results show this patient-centered solution matches the efficacy of TMS for treatment-resistant depression, while offering a safer, more convenient, and scalable alternative to both trial and error pharmaceuticals and more invasive surgical implants.
Inner Cosmos is led by CEO and founder Meron Gribetz, a deep tech visionary known for founding Meta that Facebook bought and changed their name to, and pioneering advances in spatial computing and neurotechnology.
Inner Cosmos is positioned to set a new standard of care for depression. The company is raising funds to advance development and prepare for a pivotal FDA trial in 2026. If you’re interested in learning more about this investment opportunity, I’d be happy to provide a deck and/or arrange a meeting with the team.
Thank you for your consideration.
Kind regards,
Janet
Janet M. Kagan
Managing Director
FORCE Family Office
1460 Broadway
New York, N.Y. 10036
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory body. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical facts and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.